Samsung Biologics and Biogen Idec Inc. have agreed to invest US$300 million to form a biosimilars joint venture, Samsung Group said Tuesday, the conglomerate's latest move to expand into healthcare as a new revenue source. Samsung Biologics will contribute $255 million and control an 85 percent stake in the venture and Biogen Idec will hold the remaining 15 percent stake in the venture, Samsung said in a statement. The venture will be established in March 2012 in Incheon, 40 kilometers west of Seoul, and will develop, manufacture and market biosimilars, officially approved copycat medicines developed after patents for the original biopharmaceuticals expire. Samsung Biologics is Samsung's biopharmaceutical manufacturing unit formed in April 2011, as part of Samsung's plan to diversify its businesses outside its mainstay consumer electronics and mobile devices and seek new cash sources. "At Samsung, one of our goals is to help patients around the world by increasing the accessibility and affordability of existing medicines," Kim Tae-han, chief executive of Samsung Biologics, said in a statement. "Since many of the world's top-selling drugs are biologics, developing and making high-quality biosimilars is critical to that goal."
GMT 09:14 2017 Wednesday ,18 October
Is facial recognition the stuff of sci-fi? Not in ChinaGMT 08:31 2017 Saturday ,23 September
Vision 2030 will take Saudi Arabia into the futureGMT 20:37 2017 Thursday ,07 September
NASA captures images of strong solar flaresGMT 20:39 2017 Wednesday ,30 August
United Technologies near deal to buy Rockwell Collins: reportGMT 13:41 2017 Saturday ,19 August
Eclipse-chasers trot the globe, addicted to Moon's shadowGMT 17:47 2017 Wednesday ,16 August
NASA: let's say something to Voyager 1 on 40th anniversary of launchGMT 16:41 2017 Friday ,11 August
Asteroid to shave past Earth on Oct 12: ESAGMT 21:32 2017 Tuesday ,18 July
Japanese engineers develop headset-less VR systemMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Send your comments
Your comment as a visitor